| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q1 2023 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SPDR S&P 500 ETF TR | 23 | Q3 2020 | 71.4% |
| SEATTLE GENETICS INC | 22 | Q2 2019 | 3.7% |
| MORGAN STANLEY | 22 | Q2 2019 | 1.7% |
| VANGUARD INTL EQUITY INDEX F | 18 | Q3 2015 | 100.0% |
| BIOMARIN PHARMACEUTICAL INC | 18 | Q2 2019 | 3.3% |
| MICROSOFT CORP | 17 | Q1 2018 | 1.9% |
| CITIGROUP INC | 16 | Q2 2019 | 1.4% |
| GENOMIC HEALTH INC | 15 | Q3 2019 | 3.6% |
| EXPRESS SCRIPTS HLDG CO | 15 | Q1 2018 | 3.8% |
| ACADIA PHARMACEUTICALS INC | 14 | Q2 2019 | 3.8% |
View EMORY UNIVERSITY's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| GeoVax Labs, Inc. | March 29, 2018 | 4,621,405 | 3.5% |
| Geovax Labs, Inc. | October 10, 2006 | 233,905,253 | 33.0% |
View EMORY UNIVERSITY's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-06 |
| 13F-HR | 2024-02-01 |
| 13F-HR | 2020-11-16 |
| 13F-HR | 2020-08-11 |
| 13F-HR | 2020-05-15 |
| 13F-HR | 2020-02-13 |
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-09 |
| 13F-HR | 2019-02-12 |
View EMORY UNIVERSITY's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.